Considering that reactivation of a latent infection or a higher susceptibility for a new infection with Leishmania is a severe adverse effect of immunosuppressive anti-TNFα treatment, our findings contribute to a better understanding of the effectiveness of different TNFα blockers and will be helpful for the assessment of immunosuppressive anti-TNFα agents. This evidence concerns the gene TNF and infection.